Title | Epigenetic and transcriptional control of interferon-β. |
Publication Type | Journal Article |
Year of Publication | 2021 |
Authors | Daman AW, Josefowicz SZ |
Journal | J Exp Med |
Volume | 218 |
Issue | 9 |
Date Published | 2021 09 06 |
ISSN | 1540-9538 |
Keywords | CCAAT-Enhancer-Binding Proteins, DNA Methylation, Enhancer Elements, Genetic, Epigenesis, Genetic, Gene Expression Regulation, Host-Pathogen Interactions, Humans, Influenza A Virus, H5N1 Subtype, Interferon-beta, Promoter Regions, Genetic, SARS-CoV-2, Transcription, Genetic, Ubiquitin-Protein Ligases |
Abstract | The three classes of interferons (IFNs) share the ability to inhibit viral replication, activating cell transcriptional programs that regulate both innate and adaptive responses to viral and intracellular bacterial challenge. Due to their unique potency in regulating viral replication, and their association with numerous autoimmune diseases, the tightly orchestrated transcriptional regulation of IFNs has long been a subject of intense investigation. The protective role of early robust IFN responses in the context of infection with SARS-CoV-2 has further underscored the relevance of these pathways. In this viewpoint, rather than focusing on the downstream effects of IFN signaling (which have been extensively reviewed elsewhere), we will summarize the historical and current understanding of the stepwise assembly and function of factors that regulate IFNβ enhancer activity (the "enhanceosome") and highlight opportunities for deeper understanding of the transcriptional control of the ifnb gene. |
DOI | 10.1084/jem.20210039 |
Alternate Journal | J Exp Med |
PubMed ID | 34297037 |
PubMed Central ID | PMC8313408 |
Grant List | I14-0020 / / STARR Cancer Consortium / F31 HL152706 / HL / NHLBI NIH HHS / United States R01AI148416-S1 / NH / NIH HHS / United States R01 AI148416 / AI / NIAID NIH HHS / United States T32 AI134632 / AI / NIAID NIH HHS / United States T32 AI134632 / NH / NIH HHS / United States |
Related Faculty:
Steven Josefowicz, Ph.D.